ClinicalTrials.gg
Active, not recruitingNCT01357772TAM-01Updated Jul 17, 2023

Trial of Low Dose Tamoxifen in Women With Breast Intraepithelial Neoplasia - Long Term Follow-up

A Phase 3 interventional study of Tamoxifen and placebo in Carcinoma, Intraductal, Noninfiltrating, Recurrence, Local Neoplasm and Breast Neoplasms, sponsored by Andrea DeCensi. Active, not recruiting at 14 sites in Italy. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-07-17.

Sponsored by Andrea DeCensi · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 2 years 6 months after the study started (first participant enrolled Nov 2008, registered May 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
500
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating — 4 open to participants now, 6 under way, 3 of them phase 3. Tamoxifen · Carcinoma, Intraductal, Noninfiltrating.

Enrollment
7th of 15
500 · median 262
Started
2008
with 1 other
Phase 3
5 of 16
1 open now
Registered
10th of 16
by date
Lead sponsor
1 of 16
Andrea DeCensi

Among the 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating, this one is the 7th largest by enrollment of the 15 interventional ones that give a count, is one of 2 that started in 2008, is one of 5 in phase 3, and was the 10th registered.

Carcinoma, Intraductal, Noninfiltrating

287 studies on the registry are indexed under Carcinoma, Intraductal, Noninfiltrating; 56 are open to participants now.

Browse Carcinoma, Intraductal, Noninfiltrating studies →

Open to participants now

4 of the 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About tamoxifen

Tamoxifen: first FDA approval 1977 (NOLVADEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 42 Carcinoma, Intraductal, Noninfiltrating studies recruiting now, 33 (79%) set no upper age limit and 5 (12%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing tamoxifen in Carcinoma, Intraductal, Noninfiltrating, or all of them as a file.
02

Study summary

The aim of the study is to evaluate whether tamoxifen at a low dose of 5mg/d reduces in the long term the incidence of invasive breast cancer and ductal carcinoma in situ, DCIS (DIN 1c, 2, 3) of the breast, in woman operated for lobular intraepithelial neoplasia (LIN1, 2 and 3) or ER-positive ductal intraepithelial neoplasia (DIN 1b, DIN2, DIN3, 1a excluded) of the breast.

To improve the risk-benefit ratio, the use of lower doses of the drug has been proposed.

Biomarker trials revealed that 5 mg/d was noninferior to 20 mg/d in inhibiting proliferation of breast cancer and normal endometrial tissue.

By contrast, the risk of endometrial cancer si dose-dependent, and the dose reduction can lead a substantial decrease. Morover a dose of 5 mg/day is associated with an overall decrease of the estrogenic activity of tamoxifen on insulin like growth factor (IGF-I), sex hormone-binding globulin (SHBG) and antithrombin-III, with a decrease of venous thromboembolic events. Moreover, tamoxifen exhibits a high tissue distribution, so that a dose of 5 mg/day attains at the breast tissue level a concentration 10 times higher than that needed to inhibit cell growth in vitro.

A prospective cohort study also showed that 10 mg on alternate days halves recurrence of DCIS in postmenopausal women.

It has been shown that the treatment of dysplasia or pre-cancer drives the reduction of the invasive neoplasms onset. This is a chemoprevention trial designed to validatate the low-dose Tamoxifen in women with diseases at high evolutionary risk. The demonstration of efficacy and safety of such a treatment for the prevention of the invasive breast cancer would lead improvements in term of survival and quality of life for the patients at increased risk.

Read the detailed description

Italian, multicenter, phase III trial: controlled, parallel group comparision, randomized (1:1) duble blind, tamoxifen 5 mg/d versus placebo administered for 3 years. A total of 500 women 75 years of age or younger with newly diagnosed non-invasive breast cancer have been included in the study. The long-term study implies a minimum 10 year follow up after treatment completion.

03

Conditions studied

  • Carcinoma, Intraductal, Noninfiltrating
  • Recurrence, Local Neoplasm
  • Breast Neoplasms
  • Atypical Hyperplasia

Keywords

  • DCIS
  • tamoxifen
  • dose reduction
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Women of age ≥ 18 and \< 75 years
  2. Women operated on for lobular (LIN 2 and 3) or ER positive or unknown ductal DCIS, i.e DIN 1-3, but DIN 1a excluded) intraepithelial neoplasia in the 5 years (60 months) prior the inclusion in the study. Both incident (diagnosis \< 12 months) and prevalent cases diagnosis ≥12, and \< 60 months) will be included, including recurrent cases
  3. Performance status ≤ 1
  4. Written

Exclusion criteria

Exclusion Criteria:

  1. Any type of , with the exclusion of non-melanoma skin cancer
  2. Proliferative disorders of the endometrium such as atypical hyperplasia, endometriosis, unresected polyps, symptomatic myoma
  3. Liver, kidney and heart function impairment grade ≥ 2 ( criteria v.3.0)
  4. Any type of retinal disorders, severe cataract and glaucoma
  5. Presence of significant risk factors for venous events, including immobilization after trauma within the last 3 months for longer than 2 weeks, deep venous thrombophlebitis or other significant venous thrombotic event,VTE (pulmonary embolism, stroke, etc.)
  6. Use of tamoxifen, raloxifene or other selective estrogen receptor modulator (SERMs)
  7. Use of anastrozole and other aromatase inhibitors (AI) in the last 12 months for ≥ 6 months
  8. Dicoumarol anticoagulant therapy in progress
  9. Active infections
  10. Severe psychiatric disorders or inability to comply to the protocol procedures
  11. Geographic inaccessibility or difficulties in ensuring adequate compliance
  12. Women who are pregnant or breastfeeding
  13. Any other factor which, at the discretion of the investigator, may controindicate the use of tamoxifen
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
500 participants (actual)

Study arms

  • Experimental
    Tamoxifen

    tamoxifen at daily dose of 5 mg for a total treatment time of 3 years

    Drug: Tamoxifen

  • Placebo comparator
    placebo

    placebo at daily dose of 5 mg for a total treatment time of 3 years

    Drug: placebo

Interventions

  • Also known as: Tamoxifen citrate (ATC code: L02BA01)

  • Drugplacebo
06

What researchers measure

Primary outcomes

  1. Number of invasive breast cancer events and DCIS

    Number of neoplastic events, i.e., invasive breast cancer or ductal carcinoma in situ of the breast from the start of treatment up to at least 16 years from treatment initiation.

    Time frame: 20 years

Secondary outcomes

  1. Number of other non-invasive breast events

    Number of other non-invasive breast disorders (LCIS, atypical ductal or lobular hyperplasia), endometrial cancer, ovarian cancer, thromboembolic events; bone fractures, cardiovascular and thromboembolic events, clinically manifested cataracts and melanoma; change of mammographic density from the start of treatment up to at least 16 years from treatment initiation.

    Time frame: 20 years

  2. Metabolites of tamoxifen and hormone blood level (in a subgroup of women)

    Blood concentrations of metabolites including circulating IGF-I,IGFBP-3, SHBG, hormones (testosterone, estradiol, SHBG, CRP), tamoxifen metabolites (4OH tamoxifen and endoxifen).

    Time frame: 20 years

  3. CYP2D6 polymorphisms analysis

    Esploratory analisis of some SNPS of the cytochrome P450 genes involved in tamoxifen metabolism such as CYP2D6.

    Time frame: 20 years

07

Study locations

14 sites
08

References and documents

Publications

  • DeCensi A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Ponti A, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Briata IM, Buttiron Webber T, Boni L, Bonanni B. Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clin Cancer Res. 2021 Jul 1;27(13):3576-3583. doi: 10.1158/1078-0432.CCR-20-4213. Epub 2021 Feb 19. PubMed 33608319 ↗
  • Lazzeroni M, Serrano D, Dunn BK, Heckman-Stoddard BM, Lee O, Khan S, Decensi A. Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Res. 2012 Oct 29;14(5):214. doi: 10.1186/bcr3233. PubMed 23106852 ↗
  • DeCensi A, Johansson H, Helland T, Puntoni M, Macis D, Aristarco V, Caviglia S, Webber TB, Briata IM, D'Amico M, Serrano D, Guerrieri-Gonzaga A, Bifulco E, Hustad S, Soiland H, Boni L, Bonanni B, Mellgren G. Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ Breast Cancer. 2021 Mar 25;7(1):34. doi: 10.1038/s41523-021-00236-6. PubMed 33767162 ↗
  • Lazzeroni M, Puntoni M, Guerrieri-Gonzaga A, Serrano D, Boni L, Buttiron Webber T, Fava M, Briata IM, Giordano L, Digennaro M, Cortesi L, Falcini F, Serra P, Avino F, Millo F, Cagossi K, Gallerani E, De Simone A, Cariello A, Aprile G, Renne M, Bonanni B, DeCensi A. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Recurrence in Breast Noninvasive Neoplasia: A 10-Year Follow-Up of TAM-01 Study. J Clin Oncol. 2023 Jun 10;41(17):3116-3121. doi: 10.1200/JCO.22.02900. Epub 2023 Mar 14. PubMed 36917758 ↗
  • DeCensi A, Puntoni M, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Taverniti C, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Branchi D, Campora S, Petrera M, Buttiron Webber T, Boni L, Bonanni B. Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. J Clin Oncol. 2019 Jul 1;37(19):1629-1637. doi: 10.1200/JCO.18.01779. Epub 2019 Apr 11. PubMed 30973790 ↗

Individual participant data

Plan to share: Yes — Authors are open to share data based on a request for collaboration that includes a data analysis plan. Please send an e-mail to both: andrea.decensi@galliera.it; mpuntoni@ao.pr.it

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2008 to primary completion in Dec 2022, 169 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2011
First posted
May 23, 2011
StartActual
Nov 12, 2008
Primary completionActual
Dec 31, 2022
CompletionEst.
Dec 31, 2028
Last update
Jul 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01357772
Lead sponsor
Andrea DeCensi
Collaborators
Associazione Italiana per la Ricerca sul Cancro, European Institute of Oncology
Responsible party
Andrea DeCensi (Medical Oncology Director, Ente Ospedaliero Ospedali Galliera) — Sponsor-investigator
First posted
May 23, 2011
Start date
Nov 12, 2008
Primary completion
Dec 31, 2022
Completion
Dec 31, 2028 (estimated)
Last update
Jul 17, 2023

Study contacts

Andrea DeCensi, MD
principal investigator · E.O.Ospedali Galliera

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamoxifen

Start the discussion